Healthcare Global Enterprises · NSE: HCG · BSE: 539787

Q3 FY23 results · Oct–Dec 2022

Healthcare Global Enterprises reported revenue from operations of ₹424.68 crore (up 18.6% from Q3 FY22) and net profit of ₹4.20 crore for Q3 FY23 (Oct–Dec 2022), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY23	Q3 FY22	YoY	Q2 FY23	QoQ
Revenue from operations	424.68	358.06	+18.6%	420.00	+1.1%
Other income	3.65	2.92	+25.0%	1.97	+85.3%
Total income	428.33	360.98	+18.7%	421.97	+1.5%
Profit before share of associates & JVs and tax	11.31	(46.13)	Turned profit	10.02	+12.9%
Share of profit/(loss) of associates & JVs	(0.01)	(0.01)		0.00
Net profit for the period	4.20	(49.80)	Turned profit	5.29	−20.6%
Attributable to shareholders of the company	7.54	(45.78)	Turned profit	7.38	+2.2%
EPS, basic (₹)	0.54	(3.55)	Turned profit	0.53	+1.9%
Net margin (%)	1.0	-13.9		1.3

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY23	Q3 FY22	YoY	Q2 FY23	QoQ
Revenue from operations	252.68	215.51	+17.2%	253.07	−0.2%
Other income	2.10	1.97	+6.6%	1.27	+65.4%
Total income	254.78	217.48	+17.2%	254.34	+0.2%
Profit before tax	19.38	(37.86)	Turned profit	13.92	+39.2%
Net profit for the period	14.16	(39.13)	Turned profit	11.00	+28.7%
EPS, basic (₹)	1.02	(3.03)	Turned profit	0.79	+29.1%
Net margin (%)	5.6	-18.2		4.3

Consolidated

Filed with BSE: 10 Feb 2023, 10:29 IST
Board meeting: 09 Feb 2023
Period: 01 Oct 2022 to 31 Dec 2022
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 10 Feb 2023, 10:29 IST
Board meeting: 09 Feb 2023
Period: 01 Oct 2022 to 31 Dec 2022
Review status: Unaudited
Source: XBRL filing on BSE